MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Home・Lista de Ações・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Fechado

SetorSaúde

25.91 0.23

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

25.5

Máximo

26.01

Indicadores-chave
By Trading Economics
Rendimento	-85K 53M
Vendas	4.2M 153M
P/E Médio do Setor	15.083 63.808
EPS	0.68
Margem de lucro	34.53
Funcionários	182
EBITDA	612K 81M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+33.46% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	151M 3.1B
Abertura anterior	25.68
Fecho anterior	25.91

Sentimento de Notícias

By Acuity

50%

162 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

N/A / 24.28 Suporte e Resistência

Catalyst Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de abr. de 2026, 23:26 UTC

Ações em Alta

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 de abr. de 2026, 20:41 UTC

Grandes Movimentos do Mercado

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 de abr. de 2026, 23:49 UTC

Conversa de Mercado

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 de abr. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Decline After Hitting Record High -- Market Talk

16 de abr. de 2026, 23:33 UTC

Conversa de Mercado

Notícias Principais

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 de abr. de 2026, 22:51 UTC

Conversa de Mercado

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 de abr. de 2026, 22:08 UTC

Ganhos

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 de abr. de 2026, 22:06 UTC

Ganhos

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Tech, Media & Telecom Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Notícias Principais

Basic Materials Roundup: Market Talk

16 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Ganhos

Health Care Roundup: Market Talk

16 de abr. de 2026, 20:49 UTC

Ganhos

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 de abr. de 2026, 20:43 UTC

Ganhos

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 de abr. de 2026, 20:40 UTC

Conversa de Mercado

Ganhos

Global Equities Roundup: Market Talk

16 de abr. de 2026, 20:40 UTC

Conversa de Mercado

Ganhos

Netflix Says Engagement Quality Hits New High -- Market Talk

16 de abr. de 2026, 20:30 UTC

Ações em Alta

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 de abr. de 2026, 20:25 UTC

Ganhos

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 de abr. de 2026, 20:23 UTC

Ganhos

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 de abr. de 2026, 20:19 UTC

Ganhos

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 de abr. de 2026, 20:17 UTC

Ganhos

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 de abr. de 2026, 20:17 UTC

Ganhos

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 de abr. de 2026, 20:16 UTC

Ganhos

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Comparação entre Pares

Variação de preço

Catalyst Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

33.46% parte superior

Previsão para 12 meses

Média 34.5 USD 33.46%

Máximo 35 USD

Mínimo 33 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Catalyst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

Comprar

Manter

Vender

Com base em 5 analistas que deram avaliações de ações para Catalyst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

N/A / 24.28Suporte e Resistência

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimento

By Acuity

162 / 348 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.